Tao Feng
Principal Biostatistician
Cancer
MED Source
United Arab Emirates
Biography
Tao Feng joined MedSource in June 2017 as the Principal Biostatistician. He attended University of Southern California, where he earned his PhD and Masters of Science while majoring in biostatistics. He has extensive experience in biostatistics analysis in both industrial clinical trials and academic clinical research. His methodology for clinical trial design covers both Frequentist and Bayesian approaches. Prior to joining MedSource, he was a Lead Biostatistician at a large CRO where he led Phase I to III clinical trials. As Lead Biostatistician, his responsibilities included writing statistical analysis plans for various projects and reports. He has a wide range of experience in SAS programming, validation, data transfers and working with clinical SAS programmers to ensure the accuracy of summary tables, listings, and graphs. He has experience with database management, creating biostatistics databases, investigating and clarifying data issues, managing biostatistics timelines and coordinating and validating the data transfer processes. He also has experience tracking and managing project budgets, developing bids and contract modification costs, reviewing medical writing reports, assisting with protocol development by writing the statistical portions, reviewing protocols for consistency, providing sample size calculations, performing simulations to help clients understand a project, submitting IND supplemental statistical sections to FDA, and upholding DSMB Guidelines on all projects. He was also a technical consultant of a Bayesian Analysis Initiative and helped biostatisticians to design, execute and report on Bayesian Analysis supporting Phase I-III clinical trials. In the past, he worked as a lead biostatistician for the medical oncology department at City of Hope National Medical Center. While there, he led all biostatistics analyses and activities on phase IV clinical research for the Cancer and Aging Research Group and published about 20 papers in the top peer review journals.
Research Interest
Cancer